Related Experiment Video
Updated: Apr 15, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke
Malgorzata Pawelczyk1, Henryk Chmielewski1, Beata Kaczorowska1
1Department of Neurology and Strokes, Medical University of Lodz, Lodz, Poland.
Insights
Simvastatin therapy significantly reduces platelet activation and reactivity in hyperlipidemic stroke patients. This lipid-lowering treatment offers additional benefits beyond cholesterol reduction by inhibiting platelet aggregation.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hematology
Background:
- Elevated low-density lipoprotein cholesterol (LDL-C) is linked to increased platelet activation.
- Statin therapy, including simvastatin, demonstrates pleiotropic effects, notably platelet inhibition.
- This interplay between platelet activity and statins is crucial for reducing ischemic stroke risk.
Purpose of the Study:
- To investigate the impact of simvastatin on platelet activation markers in hyperlipidemic patients post-ischemic stroke.
- To assess changes in platelet CD62P expression, soluble P-selectin (sP-selectin), and platelet-derived microparticles (PDMPs).
Main Methods:
- Studied 21 hyperlipidemic stroke patients and 20 healthy controls.
- Assessed CD62P expression on resting and thrombin-activated platelets via flow cytometry.
- Measured sP-selectin and PDMPs before and after 6 months of simvastatin (20 mg/day) treatment.
Main Results:
- Hyperlipidemic patients exhibited higher CD62P+ platelets and thrombin reactivity than controls.
- Simvastatin therapy significantly reduced resting and activated CD62P+ platelets (p = 0.005, p = 0.001).
- A significant decrease in sP-selectin levels (p = 0.001) and PDMPs (p < 0.05) was observed.
Conclusions:
- Simvastatin therapy offers benefits beyond lipid reduction in stroke patients with hyperlipidemia.
- HMG-CoA reductase inhibitor therapy plays a significant role in reducing platelet activation and reactivity.
- This suggests a dual therapeutic role in managing cardiovascular risk.
Introduction:
Low-density lipoprotein cholesterol (LDL-C) has been reported to increase platelet activation. Reducing the level of LDL-C with statins induces important pleiotropic effects such as platelet inhibition. This association between platelet activity and statin therapy may be clinically important in reducing the risk of ischemic stroke. We investigated the effect of simvastatin therapy on platelet activation markers (platelet CD62P, sP-selectin, and platelet-derived microparticles (PDMPs)) in hyperlipidemic patients after ischemic stroke.
Material And Methods:
The study group consisted of 21 hyperlipidemic patients after ischemic stroke confirmed by CT, and 20 healthy subjects served as controls. We assessed the CD62P expression on resting and thrombin-activated blood platelets. CD62P and PDMPs were analyzed by the use of monoclonal antibodies anti-CD61 and anti-CD62 on a flow cytometer. The level of sP-selectin in serum was measured by the ELISA (enzyme-linked immunosorbent assay) method. All markers were re-analyzed after 6 months of treatment with simvastatin (20 mg/day).
Results:
Hyperlipidemic patients presented a significantly higher percentage of CD62+ platelets and higher reactivity to thrombin compared to control subjects. After simvastatin therapy hyperlipidemic patients showed a reduction of the percentage of resting CD62P(+) platelets (p = 0.005) and a reduction of expression and percentage of CD62P(+) platelets after activation by thrombin (median p < 0.05; percentage: p = 0.001). A decrease of sP-selectin levels (p = 0.001) and percentage of PDMPs (p < 0.05) in this group was also observed.
Conclusions:
HMG-CoA reductase inhibitor therapy in stroke patients with hyperlipidemia may be useful not only due to the lipid-lowering effect but also because of a significant role in reduction of platelet activation and reactivity.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:23Atherosclerosis IV: Nursing Management